Regulation of Intestinal Barrier Function by Microbial Metabolites

Sweta Ghosh, Caleb Samuel Whitley, Bodduluri Haribabu, and Venkatakrishna Rao Jala

Department of Microbiology and Immunology, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky

**SUMMARY**

Gut microbial metabolites produced proximal to intestinal barrier regulate numerous host responsive activities. Current review article highlights recent advances in the area of gut metabolites and their impact on gut barrier function as well as their potential translational applications in regulating various disorders.

The human gastrointestinal tract (GI) harbors a diverse population of microbial life that continually shapes host pathophysiological responses. Despite readily available abundant metagenomic data, the functional dynamics of gut microbiota remain to be explored in various health and disease conditions. Microbiota generate a variety of metabolites from dietary products that influence host health and pathophysiological functions. Since gut microbial metabolites are produced in close proximity to gut epithelium, presumably they have significant impact on gut barrier function and immune responses. The goal of this review is to discuss recent advances on gut microbial metabolites in the regulation of intestinal barrier function. While the mechanisms of action of these metabolites are only beginning to emerge, they mainly point to a small group of shared pathways that control gut barrier functions. Amidst expanding technology and broadening knowledge, exploitation of beneficial microbiota and their metabolites to restore pathophysiological balance will likely prove to be an extremely useful remedial tool. (*Cell Mol Gastroenterol Hepatobiliary Disease* 2021;11:1463–1482; [https://doi.org/10.1016/j.jcmgh.2021.02.007](https://doi.org/10.1016/j.jcmgh.2021.02.007))

**Keywords:** Microbiota; Microbial Metabolites; Gut Barrier Function; Tight Junction Proteins; Permeability.

Humans and microbes have coevolved over millions of years, thereby contributing to the interdependency of host and microbiota physiological activities. Diverse interactive associations of host cells and microbes lead to mild to severe cellular and molecular responses depending on the status of host pathophysiological conditions. Deciphering the underlying relationship between the microbial community and human health provides a unique opportunity to utilize microbes and their metabolic products to prevent and treat numerous human disorders as well as maintain overall health. Increasing culture-independent omic-based technologies such as biomarker sequencing, metagenomics, metatranscriptomics, metaproteomics, and metabolomics have facilitated the discovery of novel functional dynamics of microbiota and their relationship with host pathophysiology. The human gut harbors abundant microbes (~10^{12}–10^{13}) that play an important role in homeostatic mechanisms leading to the regulation of numerous physiological activities both in health and disease. Microbiota significantly influence the functions of the intestinal barrier that separates internal organs from harmful entities including microorganisms, luminal antigens, and luminal proinflammatory factors. Intestinal barrier function is compromised (barrier dysfunction) in several disease conditions leading to an increased translocation of bacteria, endotoxins, and other inflammatory mediators. Gut barrier dysfunction is associated with systemic inflammatory response resulting in aggravation of the pathophysiological status of underlying diseases. Recent studies have shown a significant correlation between gut barrier dysfunction with various gastrointestinal disease conditions such as inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and celiac disease. Gut barrier dysfunction is also strongly correlated with other autoimmune, inflammatory, and metabolic diseases such as diabetes, obesity, atherosclerosis, heart failure, hypertension, and food allergies, as well as with cancer. It has been reported that various

**Abbreviations used in this paper:** AHR, aryl hydrocarbon receptor; AJ, adherens junction; ALD, alcoholic liver disease; CDCA, chenodeoxycholic acid; CLA, conjugated linoleic acid; CLDN, claudin; DCA, deoxycholic acid; DSS, dextran sulfate sodium; EA, eelagic acid; EGF, epidermal growth factor; ET, ellagittannin; FICZ, 6-formylindolo[3,2-b] carbazole; FMT, fecal microbiota transplantation; FXR, farnesoid X receptor; GF, germ free; GJ, gap junction; GLP, glucagon-like peptide; GP-BAR, G protein-coupled bile acid receptor; GPCR, G protein-coupled receptor; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; IEC, intestinal epithelial cell; IL, interleukin; LCA, lithocholic acid; LPS, lipopolysaccharide; MLCK, myosin light-chain kinase; MUC2, mucin 2; NOD, nucleotide-binding and oligomerization domain; NLR, nucleotide-binding and oligomerization domain-like receptor; OCLN, occludin; PKC, protein kinase C; SCFA, short-chain fatty acid; sEH, soluble epoxide hydrolase; TEER, transepithelial electrical resistance; TLR, Toll like receptor; TJ, tight junction; TNBS, 2,4,6-trinitrobenzene sulfonic acid; TNF-α, tumor necrosis factor alpha; TPE-CA, total phenolic extracts of Citrus aurantium L; UDCA, ursodeoxycholic acid; UroA, urolithin A; ZO, zonula occludens.
external factors like alcohol, nonsteroidal anti-inflammatory drugs, and specific pathogens can directly alter gut barrier function contributing to the pathogenesis of various diseases.\textsuperscript{12–14} The imbalance of microbes in the gut (microbial dysbiosis) has been also linked with gut barrier dysfunction and an immature immune system, leading to wide spectrum of intestinal, hepatic, and neurological disorders.\textsuperscript{15–18} Studies have revealed that fecal microbiota transplantation (FMT) from healthy hosts are positively correlated with disease reversal, especially those stemming from gut barrier dysfunction like IBD, IBS, celiac disease, and \textit{Clostridium difficile} infections.\textsuperscript{19,20}

One of the major functions of the gut microbiota is metabolism of dietary components leading to the generation of active metabolites that directly regulate human physiology including gut barrier function.\textsuperscript{21} Recent studies have explored the impact of microbial metabolites in restoration of healthy intestinal barrier function separate from their effects on immune cell functions.\textsuperscript{22–24} Detailed mechanisms are yet to be elucidated, but knowledge concerning the functional activities of metabolites on gut barrier function and the immune system is expanding gradually. Exploiting microbial metabolites to restore gut barrier integrity will prove to be an extremely useful remedial tool against several pathophysiological conditions. In this review, we discuss how the intestinal microbiota and their metabolites reinforce gut barrier function via bi-directional interactions with gut epithelial cells. Further, we will discuss potential treatment strategies to mitigate gut barrier dysfunction in various disorders.

### Table 1. Cell Types in Intestinal Barrier and Their Role in Barrier Function

| Cell types | Role in gut barrier function |
|------------|------------------------------|
| Enterocytes (small intestine, colon) | - Responsible for physical barrier through junctional protein complexes.  
- Nutrient absorbtion and metabolism.  
- Balance of epithelial shedding.  
- Secretion of antimicrobial agents.  
- Changes in expression/localization of junction proteins regulate gut barrier permeability. |
| Paneth cells (small intestine) | - Source of AMPs.  
- Directly can sense microbes and critical for gut homeostasis.  
- Paneth cell dysfunction triggers inflammation and gut barrier dysfunction.  
- Lack of Paneth cells leads to necrotizing enterocolitis both in humans and mice. |
| Goblet cells (small intestine) | - Produce and release MUCs, the mucus forming glycoprotein to maintain mucosal barrier.  
- Lack of MUC2 or O-glycan or N-glycosylation lead to severe gut barrier dysfunction and generate susceptibility to colitis. |
| Tuft cells (small intestine, colon) | - Secrete IL-25 leading to release of IL-13 from type 2 innate lymphoid cells (ILC2) to promote goblet cell hyperplasia and mucin production.  
- Detect helminth infection and expulse. |
| Enterochytopoietin cells (small intestine, colon) | - Secret hormones such as GLP-2.  
- GLP-2 induces of TJ proteins such as ZO-1 and occludin and attenuates TNF-\alpha–induced changes in TJ proteins in colon epithelial cells.  
- GLP-2 enhances epithelial cell wound healing in TGF-\beta–dependent manner. |
| M cells (small intestine) | - Antigen uptake.  
- M cell damage, during chronic inflammatory conditions elevates uptake of microorganisms amplifying the inflammatory condition leading to increased gut barrier dysfunction. |

AMP, antimicrobial peptide; GLP-2, glucagon-like peptide-2; M cell, microfold cell; MUC, mucin; TGF-\beta, transforming growth factor beta; TJ, tight junction; TNF-\alpha, tumor necrosis factor alpha.
Intestinal epithelial cells (IECs) allow for selective penetration of nutrients, water, and electrolytes while simultaneously excluding microbial pathogen-associated molecular pattern, toxins, and foreign antigens. Enterocytes connect with each other in a continuous epithelial cell layer via adhesive junctional proteins that make up tight junction (TJ) proteins, adherens junction (AJ) proteins, gap junction proteins, and desmosomes. These protein complexes not only mechanically secure extracellular cell to cell interactions, but also regulate intracellular adaptor protein–mediated interactions within gut epithelial cells. Epithelial cells tightly regulate paracellular (space between cells) and transcellular (through cell) permeability by posttranslational modifications of TJ proteins. TJ proteins are located on the apical side of the epithelial layer and form a continuous belt-like ring at the junction between the apical membrane and lateral membrane. TJ proteins consist of over 50 proteins that are crucial for maintaining cell-to-cell adhesion and gut barrier health. Some of the TJ proteins are composed of tetraspan or single-span transmembrane proteins that link to intracellular cytoskeletal proteins. TJ proteins such as occludin (OCLN), claudin (CLDN), and tricellulin are tetraspan transmembrane proteins, whereas junctional adhesion molecules are single-span transmembrane proteins. Other TJ proteins such as zonula occludens (ZO) proteins (ZO-1, ZO-2, and ZO-3) consist of intracellular scaffold proteins. The postsynaptic density protein-95/ Disc large tumor suppressor/ ZO-1 protein (PDZ) binding domains of plaque proteins (ZO-1, ZO-2, ZO-3) link the cytoskeletal proteins (eg, F-actin) and TJ complex. TJ seals are generally formed when the extracellular domains of transmembrane TJ proteins anastomose with adjacent cells. TJ proteins regulate transport molecules based on their size/charge through the paracellular space. Adherence junctions and desmosomes primarily contribute mechanical contacts between adjacent cells. The physiological structures, properties, and functions of the gut epithelial junctional protein complexes have been extensively reviewed elsewhere. The functional or physical disruption of TJ, AJ, and gap junction proteins and desmosomes leads to increased gut permeability causing dysregulated translocation/transportation of inflammatory mediators, which potentially manifests as chronic gut inflammation. Increased inflammation further perpetuates the disruption of TJ proteins leading to increased permeability. The following sections will describe gut barrier dysfunction and impact of gut microbiota and their metabolites in the regulation of the gut barrier and its altered state in various inflammatory disorders.

### Gut Barrier Dysfunction

Defective gut epithelial barrier function in combination with immune dysregulation is associated with several gastrointestinal tract–related disorders including but not limited to IBD, IBS, drug-induced toxicity, and colon cancer. Increased gut barrier permeability occurs through dysregulation of epithelial apoptosis/enterocyte death, mucus degradation, and increased paracellular permeability due to disruption of TJs. These pathways are independently regulated and functional consequences are distinct from each other. The following section describes the mechanisms and potential factors responsible for barrier dysfunction.

### TJ-Mediated Paracellular Permeability

As described in previous sections, TJ proteins are responsible for paracellular transport and selective gut barrier permeability. It was reported that solutes and water cross TJs through 2 distinct pathways based on their size and charge selectivity: the pore pathway and the leak pathway. The pore pathway is exclusively size and charge selective and excludes molecules with a diameter ≤8 Å and is a high-conductance route. CLDN-2 as well as CLDNs 10α, 10b, 15, 16, and 17 were shown to play critical role in regulation further perpetuates the disruption of TJ proteins leading to increased permeability. The following sections will describe gut barrier dysfunction and impact of gut microbiota and their metabolites in the regulation of the gut barrier and its altered state in various inflammatory disorders.

### Table 2. Structural Components of Intestinal Epithelial Cells and Gut Barrier Function

| Structural components | Junctional proteins | Examples of junctional protein–mediated intestinal barrier dysfunction |
|-----------------------|---------------------|---------------------------------------------------------------------|
| Tight junction proteins | ZO, occludin, claudins, tricellulin, JAM | - IFN-γ and TNF-α mediated organization of several TJ proteins such as ZO-1, claudin-1, claudin-4, occluding, and JAM-A downregulate intestinal epithelial barrier function. - Downregulation of claudin-3, claudin-4, claudin-5, and claudin-8 and increased claudin-2 expression and MLCK phosphorylation are reported to be associated with gut barrier function. |
| Adherens junction proteins | Cadherins, catenins | - Downregulated E-cadherin–catenin complex mediates the impairment of the integrity of mucosal barrier. |
| Desmosome | Desmoglein, desmocollins | - Desmoglein 2 (Dsg2) deficiency leads to the loss of intestinal epithelial barrier integrity. |
| Gap junctions | Connexin | - Connexin-43 plays a role in intercellular communication mediated by extracellular vesicles, tunneling nanotubes and gap junctions. |

IFN-γ: interferon gamma; JAM: junctional adhesion molecules; MLCK: myosin light-chain kinase; TNF-α: tumor necrosis factor alpha; ZO: zonula occludens.
believed to be regulated by myosin light-chain kinase (MLCK), where constitutively active MLCK is sufficient to increase the leak pathway–dependent permeability both in vitro and in vivo.\textsuperscript{52,53} It was reported that MLCK, OCLN, and ZO-1 like TJ proteins play an important role in regulation of the leak pathway.\textsuperscript{54} Detailed discussions of paracellular permeability and potential mechanisms have been published.\textsuperscript{48,49,52,55} The gut microbiota and their metabolites significantly regulate these pathways leading to either enhancement or reduction of gut barrier function.

**Unrestricted Paracellular Pathway: IEC Death**

Dysregulated IEC death is commonly observed in IBD patients as well as in preclinical models of colitis. Increased IEC death is one of the confounding factors for increased barrier breach in gastrointestinal tract–related disorders. It was reported that apoptosis, necroptosis, and pyroptosis are major cell death pathways that influence IEC death and result in pathophysiological outcomes. The mechanisms of cell death in the gut epithelium and its implication for gut barrier function and chronic inflammation are reviewed elsewhere.\textsuperscript{56} For example, Gitter et al\textsuperscript{57} showed that tumor necrosis factor alpha (TNF-\(\alpha\)) disrupts the gut barrier not only by degradation in TJs, but also through the induction of epithelial apoptosis. TNF-\(\alpha\) induced loss of the epithelial integrity due to apoptosis accounted for about 56% of the damage and the rest was by disruption of TJs in non-apoptotic areas.\textsuperscript{57} Epithelial permeability is also modulated by interleukin (IL)-13 through regulation of Cldn-2. Upregulated IL-13 and Cldn-2 induce epithelial apoptosis, resulting in epithelial barrier disruption.\textsuperscript{58} The flux that occurs due to cell death (global barrier loss) is classified as “unrestricted pathway,” in which there is no size limit of molecules or antigens that can cross the membrane.\textsuperscript{58}

**Role of Microbial Metabolites in Gut Barrier Function**

The gut microbiota is often referred to as an essential “organ” due to the vast density and richness of microbial life that exist in the gut lumen.\textsuperscript{3} Members of the gut microbiota influence host metabolic and immune status by modulating nutrient metabolism, xenobiotic and drug metabolism, and production of antimicrobial metabolites that limit numbers of competing microbes for the same niche. The following sections will discuss the role of gut microbial metabolites in regulating gut barrier function.

The host-microbiota relationship has been defined as the synergistic effect of microbial metabolites on host immunity, health and disease, energy metabolism, and cellular communication.\textsuperscript{59–63,64} Microbial metabolism contributes to the nutrient harvest from the diet. Gut microbiota metabolize dietary components and produce numerous active microbial metabolites based on the type of diet. Due to the fastidious relationship between the host immune system and microbiota, the production of helpful metabolites depends on toleration and existence of helpful microbes.\textsuperscript{64} Moreover, coevolution of host and the microbiota has apparently facilitated the production of structurally compatible microbial metabolites that bind to host receptors resulting in the modulation of host physiology.\textsuperscript{65} Recent developments in metagenomics, metatranscriptomics, and metabolomics have successfully discovered thousands of microbial metabolites and the associated genes for their synthesis. Thus far, it is estimated that ~50,000 microbial metabolites are produced by microbes in the human gut. Among these, 22,500 compounds are estimated to have antibiotic properties. Nevertheless, only 150 compounds are in direct use in human and veterinary medicine and in agriculture, reviewed in.\textsuperscript{66} It is fascinating to observe that the number of bioactive fungal products at ~8600 representing 38% of all microbial products. The description, properties, features, source, and structures of known bioactive metabolites are described elsewhere.\textsuperscript{66–71} Here, we summarize how dietary microbial metabolites influence gut barrier function.

Microbial metabolites can be classified\textsuperscript{72} as dietary product–derived metabolites, such as compound K, or de novo synthesized metabolites such as SCFAs. A third category of metabolites include metabolites that were initially generated by the host and secreted into the lumen where they undergo modification by gut microbes such as secondary bile acids. Microbial metabolites produced in the gut directly interact with IECs and immune cells and impact host health.\textsuperscript{61,62} Further, they have been shown to significantly influence the maintenance of gut barrier integrity itself and intestinal homeostasis.\textsuperscript{73,74} The following section and Table 3 summarize the immunomodulatory activities of selected microbial metabolites and their role in gut barrier function.

**Short-Chain Fatty Acids**

The human diet contains a large amount of dietary fiber and indigestible carbohydrates that escape proximal digestion and are fermented by gut commensals such as *Bifidobacterium, Bacteroides, Enterobacter, Faecalibacterium*, and *Roseburia* species into SCFAs. Propionate, butyrate, and acetate are SCFAs that not only are required for the nutritional demands of microbes, but also actively impact host immune cell differentiation and immunity and metabolism as well as regulating susceptibility to other pathogens.\textsuperscript{75–78} It was shown that sodium butyrate at a concentration ranging between 1 and 10 mM significantly improved epithelial barrier function in E12 human colon cells by increasing the levels of mucin 2 (MUC2).\textsuperscript{79} However, at higher concentrations (50–100 mM), it showed no beneficial effects on MUC2 expression patterns,\textsuperscript{79} likely due to the induction of apoptosis at higher doses. Similarly, butyrate improved barrier function at lower doses, but reduced barrier function at higher doses in Caco-2 cells.\textsuperscript{80} It was shown that butyrate induces activation of AMPK (AMP-activated protein kinase) that protects intestinal barrier integrity by facilitating the assembly of TJ proteins.\textsuperscript{81} Treatment with sodium butyrate led to the upregulation of CLDN-1 transcription by increasing the interaction between the motif specific promoter region of CLDN-1 and transcription factor SP1.\textsuperscript{82} Furthermore, Feng et al\textsuperscript{83} reported that treatment with
### Table 3. List of Microbial Metabolites, Gut Microbiota, and Their Functions

| Metabolites                                                                 | Gut Microbes                                                                 | Functions                                                                 |
|----------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Short-chain fatty acids (acetate, propionate, butyrate, valerate, isobutyrate, isovalerate, 2-methylpropionate, hexanoate) | Bacteroidetes, Firmicutes, Campylobacter jejuni, Staphylococcus aureus, Bifidobacterium sp., Coprococcus, Clostridium, Roseburia, Faecalibacterium | • Cell signaling–mediated host metabolic pathway regulation.          |
| Bacteriocin (nisin A, Mcc B17, MccJ25, colicin)                             | All major bacteria, archaea L. lactis, Klebsiella, Salmonella, Shigella, Pseudomonas, Enterobacteria (mostly Escherichia coli), S. enterica, B. cereus, S. aureus | • Transcription regulation.                                 |
| Autoinducers (AI-2, AHL, PQS)                                              | E. coli, S. aureus, P. aeruginosa, Clostridium perfringens                    | • Modulation of biofilm formation.                                     |
| Vitamins (vitamin K2, menadione, vitamin B2, vitamin B6, vitamin B9)       | Lactic acid bacteria, gram-positive organism, Bifidobacterium, S. aureus, L. monocytogenes, S. typhimurium | • Modulation of biofilm formation.                                     |
| Microbial amino acids (lysine, D-aas, D-Ser)                               | V. cholera, E. coli, P. aeruginosa, S. aureus, enterohemorrhagic E. coli      | • Modulation of biofilm formation.                                     |
| Conjugated fatty acids (sphingomyelin, acylglycerol, phosphatidylcholine, cholesterol, phosphoethanolamine) | Bifidobacterium, Enterobacter, Clostridium, Citrobacter, Roseburia, Lactobacillus, Klebsiella | • Intestinal permeability regulation.                                 |
| Indole derivatives (indole, indole-3-propionic acid, 5-hydroxyl indole, indoxyl sulfate, N-acetyltryptophan, indoxyl sulfate, serotonin, melatonin, melatonin 6-sulfate) | E. coli, C. sporogenes | • Intestinal barrier regulation.                                     |
| Bile acid metabolites (cholic acid, deoxycholic acid, chenodeoxycholic acid, taurocholic acid, lithocholic acid, glycocholic acid, ursodeoxycholic acid) | Bifidobacterium, Bacteroides, Clostridium, Lactobacillus, Enterobacter | • Intestinal barrier regulation.                                     |
| Choline metabolites (choline, methylamine, dimethylamine, trimethylamine, trimethylamine N-oxide, betaine, dimethylglycine) | Bifidobacterium, Firmicutes, Proteobacteria, Actinobacteria, Faecalibacterium prausnitzii | • Modulation of lipid metabolism.                                     |
| Phenolic, benzoyl, and phenyl derivatives (uroolithins, enterolactone, 4-OH phenylacetic acid, equol, 8-prenyl-naringenin, enterodiol) | Bifidobacterium, Lactobacillus, C. difficile, F. prausnitzii | • Metabolic biomarker.                                                |
| Polyamines (putrescine, spermidine, cadaverine, spermine)                 | Campylobacter jejuni, C. saccharolyticum                                     | • Intestinal epithelial cell and intestinal barrier integrity maintenance. |
|                                                                          |                                                                              | • Immunomodulation.                                                    |
|                                                                          |                                                                              | • Cell growth and apoptosis regulators.                                |
SCFA such as acetate, propionate, and butyrate induced expression of TJ proteins of IECs. SCFA treatment increases in paracellular transport, maintenance of ZO-1 and OCLN proteins, inhibition of NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome activation, and autophagy. In addition, gastric infusion of SCFA in a pig gut barrier model enhanced OCLN and CLDN-1 expression. High local concentrations of SCFAs also increase anion release maintaining osmotic equilibrium in the intestinal lumen for resident microbes. Importantly, consumption of diets enriched in SCFA and butyrate production by human subjects with metabolic syndrome exhibited increased colonic expression of MUC2 and OCLN, suggesting beneficial action of butyrate in gut barrier function. Moreover, butyrate treatment resulted in downregulation of IL-1β levels, suggesting it may be beneficial for protection against inflammation-promoted barrier disruption.

Indole Derivatives

A diet rich in red meat, fish, egg, cheese, cruciferous vegetables, and beans has high levels of the amino acid tryptophan. Dietary tryptophan is catabolized into indole by tryptophanase expressed by several microbes such as indole-positive *Clostridium sporogenes*. Indole and indole derivatives (such as indole-3-aldehyde, indole-3-pyruvate, indole-3-acetaldehyde, indole-3-acetamide, indole-3-propionic acid, indole-3-acetic acid, and indole-3-lactic acid) are essential for bacterial quorum sensing and intracellular signaling. Tryptophan microbial metabolites are also well-known ligands for the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that senses environmental toxins and endogenous ligands. Activation of AhR by tryptophan metabolites promotes immune cell maturation and decreased pathogen colonization. AhR signaling primarily influences the induction of immune responses via IL-22, which enhances gut barrier function (discussed in the following section). It was reported that indole levels in fecal samples of germ-free (GF) mice were 27-fold lower compared with conventionally raised mice. It was reported that responses via IL-22, which enhances gut barrier function, tryptophan. Dietary tryptophan is catabolized into indole by tryptophanase expressed by several microbes such as indole-positive *Clostridium sporogenes*. Indole and indole derivatives (such as indole-3-aldehyde, indole-3-pyruvate, indole-3-acetaldehyde, indole-3-acetamide, indole-3-propionic acid, indole-3-acetic acid, and indole-3-lactic acid) are essential for bacterial quorum sensing and intracellular signaling. Tryptophan microbial metabolites are also well-known ligands for the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that senses environmental toxins and endogenous ligands. Activation of AhR by tryptophan metabolites promotes immune cell maturation and decreased pathogen colonization. AhR signaling primarily influences the induction of immune responses via IL-22, which enhances gut barrier function (discussed in the following section). It was reported that indole levels in fecal samples of germ-free (GF) mice were 27-fold lower compared with conventionally raised mice. Importantly, supplementation of indole capsules restored gut barrier integrity by elevating junctional protein expression in GF mice. FMT has resulted in enhanced metabolic functions of gut microbiota associated with indole alkaloid biosynthesis such as indole-3-acetic acid that in turn enhances gut barrier homeostasis.

Activation of AhR by tryptophan ligands such as 6-formylindolo(3,2-b) carbazole (FICZ) enhances gut barrier function. AhR activation by FICZ was therapeutic in the dextran sodium sulfate (DSS)-induced mouse colitis model in which FICZ treatment upregulated TJ protein expression in inflamed mouse colons. Treatment with FICZ diminished MLCK expression and MLC in DSS-induced colitis mice. In addition, FICZ also prevented a TNF-α/interferon gamma–induced decrease in transepithelial electrical resistance (TEER) and disruption of TJ proteins in Caco-2 monolayers. FICZ was also shown to reverse hypoxia-induced barrier dysfunction. Thus, tryptophan agonists regulate multiple pathways in gut barrier integrity.

An impaired capacity of gut microbiota to metabolize tryptophan into multiple AhR agonists has been associated with metabolic syndrome in humans and mice. Dietary supplementation with synthetic AhR agonists or bacterial strains that naturally produce AhR ligands by Tryptophan metabolism enhanced gut barrier function via secretion of incretin hormone glucagon-like peptide-1. AhR-/mice exhibit increased inflammation and severe colitis phenotypes compared with wild type mice in the 2,4,6-trinitrobenzene sulfonic acid (TNBS) or DSS-induced colitis models. Levels of TJ proteins in AhR-/mice are also significantly reduced compared with wild type mice leading to increased gut leakiness. Additionally, AhR deficiency is associated with loss of intraepithelial lymphocytes, group 3 innate lymphoid cells and decreased IL-22 production. It was demonstrated by the Stockinger group that deletion of AhR in IECs led to a defective barrier and uncontrolled proliferation of intestinal stem cells, leading to increased tumors in an azoxymethane-DSS-induced colon tumorigenesis model. Supplementation of dietary AhR ligands (like I3C) guarded the intestinal stem cell niche and maintained intestinal barrier function and decreased tumor burden in the azoxymethane-DSS-induced colon tumorigenesis model. In parallel to these observations in mice, low levels of naturally occurring AhR ligands were reported in IBD patients. Supplementation with both *Lactobacillus* strains and synthetic AhR agonists ameliorated intestinal inflammation in IBD patients.

Bile Acid Metabolites

Bile acids that are synthesized in the liver from cholesterol in pericanalicular hepatocytes are referred to as primary bile acids. These primary bile acids, cholic acid and chenodeoxycholic acid (CDCA), are transported into the gut through the enterohepatic circulation system and are further metabolized by gut microbiota by dehydroxylation, dehydroxylation, and epimerization to generate secondary bile acids reviewed previously. Secondary bile acids include deoxycholic acid (DCA), ursodeoxycholic acid, and ursodeoxycholic acid (UDCA), and lithocholic acid (LCA) in humans. Cholic acid, CDCA, 6-hydroxylated bile acids, and muricholic acid are the primary bile acids in mice, which further converted into the secondary bile acids DCA, ursodeoxycholic acid, UDCA, muricholic acid, and hyodeoxycholic acid. Secondary bile acids antagonize the nuclear membrane farnesoid X receptor (FXR) and the G protein–coupled receptor TGR5 in the intestines. There are numerous studies published describing the impact of bile acids and their receptors on gut barrier function. Some bile acid metabolites can both improve as well as exert negative effects on gut barrier TJ function. For example, it was shown that the primary bile acid CDCA and its 7α-dehydroxylated derivative LCA have opposite effects on epithelial integrity in human colonic T84 cells. Treatment with CDCA decreased the expression of Ocln and TEER values leading to increased...
permeability as well as an increase in the inflammatory cytokine IL-8. Although LCA by itself neither altered barrier function nor increased IL-8 production, LCA attenuated CDCA-induced barrier permeability and IL-8 production. It was shown that high fat diet-induced impairment of gut barrier function is associated with the proportion of UDCA vs DCA.\textsuperscript{105,107} Mice fed a diet containing DCA exhibited increased gut permeability (>1.5-fold) compared with mice fed a regular diet. In contrast, UDCA did not alter gut permeability but blocked the DCA-induced permeability in murine jejunal and colonic preparations. Mechanistically, DCA-induced tissue disruption is responsible for DCA-mediated increased permeability rather than DCA acting as an inflammatory mediator. Further, DCA exacerbated lipopolysaccharide (LPS)-induced barrier disruption.\textsuperscript{107} Using a Caco-2 cell model, Raimondi et al\textsuperscript{110} showed that DCA and CDCA, but not UDCA, treatment decreased TEER and increased permeability. This study concluded that DCA and CDCA modulated intestinal permeability via endothelial growth factor (EGF) receptor autophosphorylation, OCLN dephosphorylation, and rearrangement at the TJ level.\textsuperscript{110} The effects of these bile acids were mediated by the Src family kinases and was abolished by EGF treatment.\textsuperscript{110} A study on prematurely weaned piglets reported that administration of CDCA improves the gut barrier protection by inducing expression of ZO-1 and reducing expression of TNF-α, IL-6, and IL-10.\textsuperscript{111} It was showed that mice exposed to broad-spectrum antibiotics such as ampicillin, clindamycin and streptomycin resulted in reduced gut bacterial diversity and richness and impacted gut barrier integrity.\textsuperscript{112} The homeostasis of bile acids was significantly changed in these mice. Further, treatment with dietary flavanones and their glycosyl derivatives such as total phenolic extracts of Citrus aurantium L (TPE-CA) restored bacterial diversity and improved gut barrier integrity and homeostasis of bile acids. TPE-CA treatment induced the expression of TJ proteins such as ZO-1 and OCLN-associated proteins in these mice and improved the barrier integrity.\textsuperscript{112} Moreover, treatment with TPE-CA maintained the homeostasis of bile acid by regulating bile acid entry into the enterohepatic circulation through farnesoid X receptor (FXR)/fibroblast growth factor 15 pathway and FXR-targeted protein.\textsuperscript{112}

Alcoholic liver disease (ALD) is associated with gut microbial dysbiosis,\textsuperscript{113–115} and ALD-associated microbiota changes lead to alterations in bile acid profiles (ie, increased amounts of unconjugated bile acids in the small intestine).\textsuperscript{116} Fexaramine, an intestine-restricted FXR agonist, restored intestinal FXR activity and gut barrier integrity in an ALD model. These studies suggested that targeted interventions can improve bile acid-FXR-fibroblast growth factor 15 signaling by modulation of hepatic Cyp7a1 and lipid metabolism, thereby reducing ethanol-induced liver disease in mice.\textsuperscript{116} The G protein–coupled bile acid receptor (GP-BAR1) (also called as TGR5) is highly expressed in the ileum and colon. The colons of GP-BAR1-/- mice exhibit altered subcellular distribution of ZO-1, leading to increased gut permeability. Importantly these mice were more susceptible to DSS- or TNBS-induced colitis.\textsuperscript{117} Mice treated with GP-BAR1 agonists (ciprofloxacin and oleanolic acid) abrogated the signs and symptoms of TNBS-induced colitis.\textsuperscript{117} In summary, bile acids have been shown to be a double-edged sword and an appropriate balance (ratio) of different bile acids is required to mediate gut barrier protective activity.

### Conjugated Fatty Acids

Intestinal bacteria such as Bifidobacterium, Butyryrivibrio, Enterobacter, Lactobacillus, Clostridium, Citrobacter, Roseburia, Klebsiella, and Megasphaera can produce conjugated fatty acid metabolites from fat-enriched diets.\textsuperscript{118} Conjugated fatty acids, such as conjugated linoleic acid (CLA), are known to influence gut barrier function. Treatment with the trans-10 CLA isomer caused a redistribution of ZO-1 and OCLN and increased paracellular permeability in Caco-2 colon epithelial cells.\textsuperscript{119} Dietary supplementation of CLA ameliorated DSS-induced colitis in mice.\textsuperscript{120} Importantly, CLA treatment reduced the prevalence of Bacteroides and increased Bifidobacterium and Odoribacter in this model. Additionally, treatment with CLA significantly increased the expression of the TJ proteins ZO-1, OCLN, and CLDN-3 in the DSS-induced colitis mouse model.\textsuperscript{120} Ren et al reported that the probiotic L. plantarum ZS2058 produced isomers of conjugated fatty acids, α-linolenic acid (conjugated linolenic acid (CLNA) 1 and CLNA2) mitigated DSS-induced colitis by enhancing gut barrier function through upregulation of ZO-1, OCLN, CLDN-3, and E-cadherin 1 in colonic tissues. Additionally, treatment with CLNA1 and CLNA2 significantly reduced inflammatory mediators (TNF-α, IL-1β, and IL-6) while upregulating the expression of the colonic anti-inflammatory cytokine IL-10 and nuclear receptor peroxisome-activated receptor-γ. These treatments also rebalanced the intestinal microbial composition in the colons of DSS-treated mice, including increasing the α-diversity.\textsuperscript{121}

### Polyamines

The polyamines such as spermine, spermidine, and putrescine have important implications in human health, mainly in the intestinal maturation and in the differentiation and development of immune system. The gut microbiota metabolize polyamine rich foods (eg, wheat germ, citrus fruits, mushrooms, soybeans) to generate polyamines in the lower intestine. Polyamines are also produced in the cytoplasm of human cells either by the enzyme ornithine decarboxylase or by AdoMetDC (S-adenosyl-methionine decarboxylase) and a transferase in the upper intestine. Polyamines exhibit numerous beneficial effects including increased longevity, recovery of injured mucosa, as well as favorable effects on cognitive function.\textsuperscript{122–124} Here, we briefly discuss the polyamine regulation of intestinal barrier integrity. Gut microbes such as E. coli, Bacteroides spp. and Fusobacterium spp. can synthesize polyamines.\textsuperscript{122} Bacterial polyamines include spermidine, homospermidine, norspermidine, putrescine, cadaverine, and 1,3-diaminopropane with putrescine and spermidine.\textsuperscript{125} Polyamines enhance gut barrier integrity through inducing E-cadherin, the cell-cell adhesion protein in
c-Myc-dependent manner.\textsuperscript{126} It was shown that depletion of cellular polyamines by α-difluoromethylornithine reduced intracellular free Ca\textsuperscript{2+} concentrations in normal IECs (IEC-6 cell line),\textsuperscript{127} which leads to decreased expression of E-cadherin and increased paracellular permeability. Interestingly, polyamine depletion does not alter expression of TJ proteins such as ZO-1, ZO-2, and junctional adhesion molecule-1. However, exogenous supplementation of the spermidine reversed the effects of α-difluoromethylornithine on intracellular Ca\textsuperscript{2+} and E-cadherin expression and restored paracellular permeability to near normal levels.\textsuperscript{128} These studies suggested that polyamines regulate gut barrier function through upregulating E-cadherin in an intracellular Ca\textsuperscript{2+}-dependent manner.\textsuperscript{127}

**Polyphenolic Derivatives**

Dietary polyphenols, which have limited bioavailability, are most abundantly present in berries, walnuts, and pomegranate. Polyphenolic compounds (eg, tannins, flavonols, flavanones, flavones, isoflavones, flavan-3-ols, lignans, chlorogenic acids, anthocyanidin) are metabolized by gut microbiota as indicated in Table 3 and converted to active phenolic derivatives responsible for numerous physiological activities. Removal of sugars by microbes leads to breakdown of glycosylated derivatives of polyphenols, which are inactive components of the human diet. Limitations in bioavailability of polyphenolic compounds are exploited by microbes via conversion into microbial-derived secondary metabolites. For example, dietary ellagic acid (EA) derivatives such as ellagittannins (ETs) are metabolized into various bioactive metabolites including urolithins (UroUthin A, B, C, D, and iso-urolithin A) by human gut microflora.\textsuperscript{129} The health benefits of consumption of pomegranate and pomegranate juice are attributed to the activities of these urolithins.\textsuperscript{130,131} Compared with ETs or EA, urolithins have a much higher rate of absorption most likely due to increased lipophilicity.\textsuperscript{132} Among urolithins, urolithin A (UroA) displays potent anti-inflammatory, antioxidative, and antiaging properties.\textsuperscript{133,134,135} However, UroA can only be detected in ~40%-50% of human subjects upon consumption of EA/ET-containing diets.\textsuperscript{131,136-143} Two factors are critical for the generation of UroA in humans (1) presence of UroA producing bacteria and (2) consumption of EA/ET-containing foods (eg, pomegranate, berries, walnuts). The concentration of serum urolithins can reach up to micromolar levels without displaying toxicity in certain populations.\textsuperscript{132,134,136,144,145} For example, upon consumption of 1L of pomegranate juice daily for 5 days by healthy volunteers, urolithin levels ranged from 0.5 to 18.6 μM in the plasma.\textsuperscript{136} It was reported that 2 species of human intestinal bacteria, *Gordonibacter urolithinfaciens*, sp. nov. and *G. pamelaeae DSM 19378(T)*, convert EA to Urolithin M-5, M-6 and C.\textsuperscript{146} Recently, *B. pseudocatenulatum* strain INIA P815 was shown to be responsible for the production of UroA and UroB by metabolizing EA.\textsuperscript{147} However, functional activities and production of UroA in vivo yet to be directly determined using gnotobiotic animals. Numerous studies have shown the beneficial activities of UroA in various pathophysiological conditions due to its anti-inflammatory, antioxidative, anticancer, and antiaging properties.\textsuperscript{134,148,149} Our group demonstrated that treatment with UroA significantly enhanced gut barrier integrity through upregulation of TJ proteins via an AhR-Nrf2-dependent pathway.\textsuperscript{22} UroA failed to upregulate TJ proteins such as Cldn4, ZO-1 and Ocln in AhR\textsuperscript{+/−} and Nrf2\textsuperscript{+/−} mice. Importantly, treatment with UroA mitigated DSS- or TNBS-induced colitis in mice through enhancing gut barrier function and blocking the production of inflammatory cytokines.\textsuperscript{22} A human phase I clinical trial showed that a polyphenol-rich diet modulates gut microbiota and reduces intestinal permeability, including decreased transport of pathogenic microbes into the bloodstream.\textsuperscript{150} Johnson et al\textsuperscript{151} reported that dietary polyphenols such as isoflavones and lignans and corresponding microbial metabolites protected the gut epithelium by reducing permeability and inhibited LPS-induced inflammation. Lignan derived microbial metabolites such as equol and enterolactone protected against nitric oxide−, TNF-α−, and IL-6−induced barrier dysfunction.\textsuperscript{151} Moreover, anthocyanins and proanthocyanidins, polyphenols form blueberries, ameliorated *E. coli*-induced gut barrier dysfunction.\textsuperscript{152}

In summary, numerous microbial metabolites discussed previously shown to exhibit direct impact on gut epithelium and play an important role in regulating gut barrier function thereby mucosal immunity and vice versa.

**Role of Bacterial Structural Components in Gut Barrier Function**

Numerous bacterial products regulate gut barrier function by activating Toll-like receptors (TLR) and nucleotide-binding and oligomerization domain (NOD)-like receptor (NLR) pathways.\textsuperscript{153-156} Here, we highlight some of the bacterial components and their receptors that participate in regulating gut barrier integrity. IECs express TLR2 that recognizes bacterial lipopeptides, lipoteichoic acid and yeast zymosan, and forms heterodimers with TLR1 or TLR6.\textsuperscript{157} Ligand-induced TLR2 activation leads to the specific activation of protein kinase C α (PKC-α) and PKC-δ and is responsible for increased TEER as well as increased apical tightening and sealing of the TJs. PKC phosphorylation by TLR2 activation leads to stabilization of ZO-1, which is a target of PKC. It was shown that the treatment with the TLR2 agonist Pam3CSK4 (PCSK [pro-protein convertase subtilisin/kexin]) increased the gap junctional intercellular communication through connexin-43 during IEC injury.\textsuperscript{158} Furthermore, Cario et al\textsuperscript{159} demonstrated using both in vitro and ex vivo models that TLR2 stimulation effectively preserves TJ-associated barrier assembly against stress-induced damage through promotion of PI3K/Akt-mediated cell survival in an MyD88-dependent manner. In this study, the authors showed that oral treatment with the TLR2 ligand, PCSK significantly suppressed mucosal inflammation and apoptosis by efficiently restoring TJ-associated integrity of the intestinal epithelium in a mouse colitis model.\textsuperscript{159} Bacterial LPS mediates proinflammatory signaling
through TLR4 and the adapter molecule MyD88. Numerous studies including ours showed that LPS disrupts junctional protein complexes and increases inflammatory cytokines leading to increased gut permeability. Blocking LPS-mediated signaling has been shown to protect against gut barrier disruption. For example, wogonin suppresses the inflammatory response and maintains intestinal barrier function via the TLR4-MyD88-TAK1 (TGF-β activated kinase 1)-NF-κB (nuclear factor-kappa B) pathway in Caco-2 cells. It was also shown that the TLR4/NF-κB signaling pathway may be critical to the mechanism underlying hypoxia-induced damage to intestinal barrier function and bacterial translocation. Importantly, treatment with a TLR4 antagonist (CRX-526) inhibited the development of disease in an acute DSS colitis model. Although blocking TLR4 with antibodies limited acute inflammation in the DSS model, subsequent tissue repair was hampered, suggesting an important role for TLR4 in the resolution of inflammation and restoration of tissue integrity. TLR4−/− mice exhibited less intestinal permeability (FITC-dextran permeability assay) compared with wild type mice in a burn injury model due to unaltered expression of the TJ protein OCLN. Overall, these studies suggest that TLR4 plays an important role in modulating gut barrier function.

Flagellin, a structural component of bacterial flagellum, is exerted activities through TLR5 and has been shown to play an essential and nonredundant role in protecting the gut from enteric microbes. It was demonstrated in numerous reports from Dr Gewirtz’s group that expression and activation of TLR5 on IECs regulates the composition and localization of microbiota and prevents disease associated intestinal inflammation. Activation of TLR5 by flagellin in ileal tissues of SAMP1/YitFc (SAMP) mice (a spontaneous model of Crohn’s disease–like ileitis) led to decreased epithelial barrier resistance and altered expression of the TJ proteins CLDN-3, OCLN, and ZO-1. Further, TLR5−/− mice developed spontaneous colitis due to increased bacterial burdens and reduced anti-inflammatory cytokine secretion. Hypomethylated CpG (cytosine-guanine dinucleotide DNA) DNA motifs (microbial CpG-DNA) are recognized by TLR9. TLR9−/− mice are more susceptible to DSS-induced colitis compared with wild types mice, suggesting that activation of TLR9 is important for protection against intestinal damage through induction of vascular EGF and intestinal progenitor cell differentiation as well as being critical for wound repair mechanisms.

NLRs proteins are also responsible for maintaining gut barrier integrity by sensing the presence of commensal microbiota and the regulation of intestinal inflammation. NLRs like NOD1 and NOD2 are expressed both on immune and epithelial cells and detect the bacterial cell wall component peptidoglycan. Activation of NLRs results in inflammatory responses mediated by NF-κB, mitogen-activated protein kinase, or caspase-1 activation. It was reported that Nod1−/− mice have increased levels of intestinal permeability and inflammation in the murine DSS-induced colitis model compared with wild type mice, suggesting an important role in intestinal barrier function. Furthermore, muramyl dipeptide or peptidoglycan mediated activation of NOD2 is reported to negatively regulate TLR signaling and provide protection of wildtype mice against colitis. The absence of NOD protein–mediated microbial sensing leads to a loss of gut barrier homeostasis and leads to increased susceptibility to gut inflammatory diseases. NOD1 and NOD2 knockout mice exhibit increased paracellular permeability and are reported to be more susceptible to DSS colitis mediated intestinal injury. Couturier-Millard et al reported that NOD2 deficiency leads to microbial dysbiosis leading to increased risk of colitis.

Additionally, the mucosal immune system profoundly impacts gut barrier functions both in health and disease conditions, reviewed previously. As discussed previously, microbial metabolites regulate host immunity by exploiting metabolite-specific immune cell receptors such as AhR, FXR, pregnane X receptor, membrane bile acid receptor (M-BAR/TGR5), purinergic receptor (P2X7), and G protein–coupled receptors (GPR41, GPR43, GPR109A). These receptors, which play crucial roles in host-microbiota interactions, are expressed at various levels in different cell types such as IECs, innate lymphoid cells, macrophages, T cells, and dendritic cells. Functional immune responses often modulate gut barrier integrity; hence, the fine tuning of gut microbiota to evoke necessary immune responses to alter intestinal barrier function is critical.

In summary, bacterial structural components either directly or indirectly (through increasing inflammatory mediators and regulating immune system) impact and modulate the gut barrier functions both in health and disease conditions.

### Treatment Strategies Against Gut Barrier Dysfunction

Microbial manipulations and supplementation of microbial metabolites are being considered as emerging preventive and therapeutic medicines for numerous disorders including those with gut barrier dysfunction and dysbiosis. Though beneficial activities of microbial metabolites in regulating gut barrier function have been shown in animal models, thus far, no microbial metabolites or their analogues are in clinical use. The following section reviews experimental approaches that could be efficacious in improving gut barrier function (Figure 1).

One approach would entail modulation of immune cell function. Conventional treatment strategies include the use of immunosuppressants such as azathioprine and mesalamine that are used in the clinic to treat ulcerative colitis and Crohn’s disease. Another therapeutic approach includes blocking Th1 responses or using neutralizing antibodies such as infliximab (anti-TNF) antibody. Altering the signaling pathways involved in gut barrier dysfunction are reported as potential therapeutics. It was shown by the Turner group that a domain binding small molecule called “divertin” blocks the recruitment of MLCK1 without inhibiting enzyme function. Further, they
showed that treatment with divertin blocked acute interferon gamma–primed TNF-induced MLC phosphorylation and barrier loss in Caco-2 monolayers model system. Importantly, they provided the evidence that treatment with divertin regulate paracellular transport rather than transcellular transport across the membranes. Further, they demonstrated that treatment with divertin corrected increased intestinal permeability in IL-10−/− mice (spontaneous colitis model) without significant systemic, mucosal, or epithelial toxicity. Treatment with divertin also reduced the progression and severity of experimental chronic colitis of T cell transfer model (CD4+ effector T cells in immunodeficient mice) by correcting gut permeability. Recent advances in defining the functional role of specific commensal bacteria has led to novel approaches to attain gut homeostasis and improve barrier function. Implantation of 17 pre-selected clostridial bacterial strains that are capable of enhancing Treg cell abundance and inducing anti-inflammatory mediators, IL-10 and inducible T-cell co-stimulator, into GF mice attenuated TNBS-induced colitis and enhanced gut barrier function. Similarly, implantation with IL-10 producing Lactococcus lactis reduced inflammation in a mouse colitis disease model. FMT is another emerging tool for treatment of gut dysbiosis as it can effectively repopulate the gut with a more favorable microflora. FMT was reported to decrease antibiotic, chemotherapy, and injury-induced gut permeability and increased the prevalence of specific microbiota strains exhibiting anti-inflammatory properties.

Several microbial metabolites are being considered as promising therapeutics against gut barrier dysfunction. As discussed above, the EA-derived microbial metabolite UroA is reported to increase intestinal barrier integrity and illustrated the opportunity for the use of microbial metabolites to treat inflammatory intestinal diseases. Our group showed that UroA and its synthetic structural analogue UAS03 enhanced gut barrier function via upregulation of TJ proteins such as CLDN-4, OCLN, and ZO-1. Additionally, UroA and UAS03 also blocked unwarranted inflammation and mitigated colitis in pre-clinical models. Oxyberberine, another microbial metabolite derived from berberine ameliorated gut barrier dysfunction via inhibition of the TLR4, MyD88, and NF-κB signaling pathways and downregulated inflammatory cytokines such as TNFα, IL-6, and IL-1β. Probiotics such as L. plantarum are reported to modulate the normal gut microbiome and maintain gut barrier homeostasis and regulate permeability by strengthening the intestinal epithelium. Furthermore, probiotic strains such as L. plantarum also elevate the levels of host defense peptides such as pBD2, PG1-5 and pBD2 and
improve gut barrier function. It was shown that a bioactive compound from *Astragalus membranaceus*, Astragaloside IV (AS-IV) induced TJ protein expression by suppressing RhoA/NLRP3 inflammasome signaling pathways in a sepsis model. Activation of mitochondrial dynamin-related protein (Drp1) regulates gut barrier function through regulating SCFA-producing gut microbiota in hemorrhagic shock mouse models. It was shown that activated Drp1 led to distribution of ZO1 protein and increased intestinal permeability in a ROS-specific manner. Further, blocking Drp1-induced ROS accumulation by N-acetylcysteine in IECs protected TJs and improved intestinal barrier function after hypoxia. Studies have shown that soluble epoxide hydrolase (sEH) and its metabolites (as dihydroxyeicosatrienoic acids) were upregulated in the colon tissues of diet-induced obese mice. It was demonstrated that increased expression of sEH led to enhanced gut permeability in diet-induced obesity models. Further, genetic deletion of sEH (sEH knockout mice) abolished obesity-induced gut leakage, endotoxin lipopolysaccharide and bacterial translocation. Pharmacological inhibition of sEH (trans-4-(4-[3-(4-trifluoromethoxyphenyl) ureido] cyclohexyloxy) benzoic acid (t-TUCB), prevented obesity-induced gut barrier dysfunction suggesting sEH inhibitors may be promising agents for gut barrier dysfunction treatment in obesity conditions.

A variety of evidence also suggests that hormone treatment can be a potential therapeutic strategy to combat barrier dysfunction. For example, sex hormones such as estrogen and progesterone induced expression of TJ proteins and inhibited gut permeability in inflammatory organoid models from IBD patients and 2D cell line models. Zhou et al. reported that progesterone upregulated OCLN expression in the gut and inhibited NF-κB activation to maintain gut barrier homeostasis. Irisin, a newly identified exercise hormone, was also reported to ameliorate gut barrier dysfunction via activation of the AMPK-UCP 2 pathway and binding to the integrin αVβ5 receptor.

Dietary component such as curcumin supplementation reduced high fat diet induced hepatic steatosis by modulating the gut-liver axis and by enhancing ZO-1 and OCLN expression in the intestines. Dietary supplements have also provided evidence for treatment of gut barrier dysfunction. Supplementation of dietary garcinol inhibited intestinal barrier dysfunction via elevated ZO-1, CLDN-1, and OCLN expression. Dietary cellulose supplements also can ameliorate LPS-mediated intestinal barrier damage and protect against gut epithelial apoptosis. However, growing evidences also suggests that certain treatments related to diseases such as sepsis, systemic inflammatory response syndrome, small bowel ischemia, hypoxia, and cancer lead to loss of gut barrier function as the result of enterocyte damage. Hence, withdrawal of treatment in some cases can also reverse gut barrier dysfunction.

Last, but definitely not the least, dietary habits and a healthy lifestyle are of the foremost importance in maintaining healthy intestinal barrier functions. Early-stage disease development as well as early detection of an imbalance of gut permeability due to external stimuli or
dietary habits can be reversed. A healthy life without stress, obesity, and diabetes and accompanied by an alcohol-free diet can reverse gut barrier dysfunction over time. Emerging knowledge of host-microbiota interactions allows for the development of new therapeutic strategies to restore a healthy gut ecosystem and prevent a variety of intestinal diseases.

Conclusions

The current review provides a summary of current understanding of the role of gut microbial metabolites in maintenance of gut barrier integrity. The review also discusses potential therapeutic targets and mechanisms of action (Figure 2). In addition, we outlined potential strategies to improve gut barrier integrity. The influence of gut microbiota on intestinal barrier permeability and subsequent host cellular homeostasis is indisputable. Intestinal microbial homeostasis is required for maintenance of good health and disease prevention. Emerging technologies have given insight into microbial dynamics and composition, stimulating the development of new hypotheses concerning microbiota function and host-microbe interactions. Thus, an in-depth understanding of the relationship between a host and its microbiota helps to elucidate detailed mechanistic understanding of pathogenesis and reveals pathways that can be modulated for disease prevention. Reversal of gut dysbiosis is the key factor for any treatment utilizing gut microbiota. In fact, studies have shown that microbial-derived metabolites largely impact pathogen colonization, gut barrier integrity, and host metabolism. Moreover, increasing recognition of the association between gut microbes, gut barrier dysfunction, and intestinal diseases highlights the importance of understanding microbial metabolite production and function. Hence, defining a “healthy” microbiota and microbial metabolites and the development of de novo multomic technologies as biomarkers and therapeutic tools will significantly advance microbiota research. Furthermore, a deeper understanding of intestinal microbiota dynamics with respect to gut barrier function provides translational opportunities for therapeutic discovery, including drug design, microbe transplantation, and a clearer perspective of host pathophysiology. Additionally, the advantages of extensive longitudinal studies highlight a direction for future investigation, which will unequivocally show the impact of external environmental factors on host physiology and on shaping the gut microbiome population in the human intestine. In a nutshell, there is hope that proper utilization of beneficial gut microbes and gut metabolites will maintain human health devoid of intestinal diseases.

References

1. Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A 2008;105:2117–2122.
2. Oh J, Byrd AL, Deming C, Conlan S, Program NCS, Kong HH, Segre JA. Biogeography and individuality shape function in the human skin metagenome. Nature 2014;514:59–64.
3. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med 2016;375:2369–2379.
4. Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature 2012;486:207–214.
5. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005;308:1635–1638.
6. Kamada N, Chen GY, Inohara N, Nunez G. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013;14:685–690.
7. Ha CW, Lam YY, Holmes AJ. Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health. World J Gastroenterol 2014;20:16498–16517.
8. Wu H, Tremaroli V, Backhed F. Linking microbiota to human diseases: a systems biology perspective. Trends Endocrinol Metab 2015;26:758–770.
9. Claesson MJ, Jeffery IB, Conde S, Power SE, O’Connor EM, Cusack S, Harris HM, Coakley M, Lakshminarayanan B, O’Sullivan O, Fitzgerald GF, Deane J, O’Connor M, Harnedy N, O’Connor K, O’Mahony D, van Sinderen D, Wallace M, Brennan L, Stanton C, Marchesi JR, Fitzgerald AP, Shanahan F, Hill C, Ross RP, O’Toole PW. Gut microbiota composition correlates with diet and health in the elderly. Nature 2012;488:178–184.
10. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell 2013;33:570–580.
11. Martini E, Krug SM, Siegmund B, Neurath MF, Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2017;4:33–46.
12. Elamin E, Mascleee A, Troost F, Pieters HJ, Keszthelyi D, Aleksa K, Dekker J, Jonkers D. Ethanol impacts intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach. PLoS One 2014;9:e107421.
13. Utzri E, Usai P. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroenterol 2017;23:3954–3963.
14. Berkes J, Viswanathan VK, Savkovic SD, Hecht G. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003;52:439–451.
15. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;108:1566–1581.
2021 Regulation of Intestinal Barrier Function by Microbial Metabolites

16. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Starkel P, Windy K, Tremaroli V, Backhed F, Verbeke K, de Timary P, Delzenne NM. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A 2014;111:E4485–E4493.

17. Gonzalez-Gonzalez M, Díaz-Zepeda C, Eyzaguirre-Velasquez J, Gonzalez-Aranicibia C, Bravo JA, Julio-Pieper M. Investigating gut permeability in animal models of disease. Front Physiol 2018;9:1962.

18. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007;104:13780–13785.

19. Moayyedi P, Sadat B, Jafari M, Boyer J, Vahedi F, Fakhraei F, Vahidi S, Abiri A. The role of intestinal barrier disruption in the pathogenesis of inflammatory bowel disease. J Clin Gastroenterol 2019;53(9):671–685.

20. Kim P, Gadani A, Abdul-Baki H, Mitre R, Mitre M. Fecal microbiota transplantation in recurrent Clostridium difficile infection: a retrospective single-center chart review. JGH Open 2019;3:4–9.

21. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013;154:39–50.

22. Singh R, Chandrashekharappa S, Bodдуluri SR, Baby BV, Hegde B, Kotla NG, Hiwale AA, Saidey T, Patel P, Vijay-Kumar M, Langille MGI, Douglas GM, Cheng X, Rouchka EC, Waigel SJ, Dryden GW, Alatassi H, Zhang HG, Haribabu B, Vemula PK, Jala VR. Enhancement of the gut barrier integrity by a microbial metabolite through the Nr2 pathway. Nat Commun 2019;10:89.

23. Ewaschuk JB, Díaz H, Meddings L, Diederichs B, Eyzaguirre J, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Starkel P, Windy K, Tremaroli V, Backhed F, Verbeke K, de Timary P, Delzenne NM. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci U S A 2014;111:E4485–E4493.

24. Anderson RC, Cookson AL, McNabb WC, Park Z, McCann MJ, Kelly WJ, Roy NC. Lactobacillus plantarum MB452 enhances the function of the intestinal barrier by increasing the expression levels of genes involved in tight junction formation. BMC Microbiol 2010;10:316.

25. Peterson LW, Artis D. Intestinal epithelial cells: regulators of barrier function and immune homeostasis. Nat Rev Immunol 2014;14:141–153.

26. Okumura R, Takeda K. Roles of intestinal epithelial cells in the maintenance of gut homeostasis. Exp Mol Med 2017;49:e338.

27. Allaire JM, Crowley SM, Law HT, Chang S-Y, Ko H-J, Vallance BA. The intestinal epithelium: central coordinator of mucusal immunity. Trends Immunol 2018;39:677–696.

28. Corfield AP. The interaction of the gut microbiota with the mucus barrier in health and disease in human. Microorganisms 2018;6:78.

29. Corfield AP, Carroll D, Myerscough N, Probert CS. Mucins in the gastrointestinal tract in health and disease. Front Biosci 2001;6:D1321–D1357.

30. Kunzelmann K, Mall M. Electrolyte transport in the mammalian colon: mechanisms and implications for disease. Physiol Rev 2002;82:245–289.

31. Niesen CM. Tight junctions/adherens junctions: basic structure and function. J Invest Dermatol 2007;127:2525–2532.

32. Groschwitz KR, Hogan SP. Intestinal barrier function: molecular regulation and disease pathogenesis. J Allergy Clin Immunol 2009;124:3–20, quiz 21–22.

33. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 2006;68:403–429.

34. Fung KYY, Fain RD, Lee WL. Transcellular vesicular transport in epithelial and endothelial cells: challenges and opportunities. Traffic 2018;19:5–18.

35. Shigetomi K, Ikemochi J. Regulation of the epithelial barrier by post-translational modifications of tight junction membrane proteins. J Biochem 2018;163:265–272.

36. Chiba H, Osanai M, Murata M, Kojima T, Sawada N. Transmembrane proteins of tight junctions. Biochim Biophys Acta 2008;1778:588–600.

37. Schulzke JD, Fromm M. Tight junctions: molecular structure meets function. Ann N Y Acad Sci 2009;1165:1–6.

38. Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123:1777–1788.

39. Furuse M, Fujita K, Hiraigaki T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998;141:1539–1550.

40. Ikemochi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005;171:939–945.

41. Garrido-Urbani S, Bradfield PF, Imhof BA. Tight junction dynamics: the role of junctional adhesion molecules (JAMs). Cell Tissue Res 2014;355:701–715.

42. Odenwald MA, Choi W, Kuo WT, Singh G, Sailer A, Wang Y, Shen L, Fanning AS, Turner JR. The scaffolding protein ZO-1 coordinates actomyosin and epithelial apical specializations in vitro and in vivo. J Biol Chem 2018;293:17317–17335.

43. Garcia-Hernandez V,Quiros M, Nusrat A. Intestinal epithelial claudins: expression and regulation in homeostasis and inflammation. Ann N Y Acad Sci 2017;1397:66–79.

44. Laukoetter MG, Bruwer M, Nusrat A. Regulation of the intestinal epithelial barrier by the apical junctional complex. Curr Opin Gastroenterol 2006;22:85–89.

45. Buckley A, Turner JR. Cell biology of tight junction barrier regulation and mucosal disease. Cold Spring Harb Perspect Biol 2018;10:A02931.

46. Farkas AE, Nusrat A. Pharmacological targeting of the inflamed intestinal barrier. Curr Pharm Des 2016;22:5400–5414.
47. Choi W, Yeruva S, Turner JR. Contributions of intestinal epithelial barriers to health and disease. Exp Cell Res 2017;358:71–77.

48. Zuo L, Kuo WT, Turner JR. Tight junctions as targets and effectors of mucosal immune homeostasis. Cell Mol Gastroenterol Hepatol 2020;10:327–340.

49. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 2009;9:799–809.

50. Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009;1:a002584.

51. Buschmann MM, Shen L, Rajapakse H, Raleigh DR, Wang Y, Wang Y, Lingaraju A, Zha J, Abbott E, McAuley EM, Breskin LA, Wu L, Anderson K, Turner JR, Weber CR. Occludin OCEL-domain interactions are required for maintenance and regulation of the tight junction barrier to macromolecular flux. Mol Biol Cell 2013;24:3056–3068.

52. Shen L, Black ED, Witkowski ED, Lencer WI, Guerriero V, Su L, Shen L, Clayburgh DR, Nalle SC, Sullivan EA, McAuley EM, Breskin LA, Wu L, Anderson K, Turner JR, Rajapakse H, Raleigh DR, Funk SJ, Buschmann MM. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009;136:511–563.

53. Yu AS, McCarthy KM, Francis SA, McCormack JM, Lai J, Rogers RA, Lynch RD, Schneeberger EE. Knockdown of occludin expression leads to diverse phenotypic alterations in epithelial cells. Am J Physiol Cell Physiol 2005;288:C1231–C1241.

54. Odenwald MA, Turner JR. The intestinal epithelial barrier: a therapeutic target? Nat Rev Gastroenterol Hepatol 2017;14:9–21.

55. Patankar JV, Becker C. Cell death in the gut epithelium and implications for chronic inflammation. Nat Rev Gastroenterol Hepatol 2020;17:543–556.

56. Gitter AH, Bendfeldt K, Schulzke JD, Fromm M. Leaks in the epithelial barrier caused by spontaneous and TNF-alpha-induced single-cell apoptosis. FASEB J 2000;14:1749–1753.

57. Heller F, Fromm A, Gitter AH, Mankertz J, Schulzke JD. Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 2008;1 Suppl 1:S55–S61.

58. Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol 2015;21:8787–8803.

59. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J 2017;474:1823–1836.

60. Li Z, Quan G, Jiang X, Yang Y, Ding X, Zhang D, Wang X, Hardwidge PR, Ren W, Zhu G. Effects of metabolites derived from gut microbiota and hosts on pathogens. Front Cell Infect Microbiol 2018;8:314.

61. Araki S, Suzuki M, Fujimoto M, Kimura M. Enhancement of resistance to bacterial infection in mice by vitamin B2. J Vet Med Sci 1995;57:599–602.

62. Donia MS, Fischbach MA. Human microbiota. Small molecules from the human microbiota. Science 2015;349:1254766.

63. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411–420.

64. Cohen LJ, Esterhazy D, Kim SH, Lemetre C, Aguilar RR, Gordon EA, Pickard AJ, Cross JR, Emiliano AB, Han SM, Chu J, Vila-Farres X, Kaplitt J, Rogoz A, Calle PY, Hunter C, Bitok JK, Brady SF. Commensal bacteria make GPCR ligands that mimic human signalling molecules. Nature 2017;549:48–53.

65. Berdy J. Bioactive microbial metabolites. J Antimicrob (Tokyo) 2005;58:1–26.

66. Bethal V. Mode of action of microbial bioactive metabolites. Folia Microbiol (Praha) 2006;51:359–369.

67. Fernandez-Navarro T, Salazar N, Gutierrez-Diaz I, Sanchez B, Ruas-Madiedo P, de Los Reyes-Gavilan CG, Margolles A, Queimonde M, Gonzalez S. Bioactive compounds from regular diet and faecal microbial metabolites. Eur J Nutr 2018;57:487–497.

68. Omura S. Thorn Award Lecture. Trends in the search for bioactive microbial metabolites. J Ind Microbiol 1992;10:135–156.

69. Umezawa H. Recent advances in bioactive microbial secondary metabolites. Jpn J Antimicrob 1977;30:138–163.

70. Zhang LS, Davies SS. Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med 2016;8:46.

71. Kho ZY, Lal SK. The human gut microbiome - a potential controller of wellness and disease. Front Microbiol 2018;9:1835.

72. Alam A, Neish A. Role of gut microbiota in intestinal wound healing and barrier function. Tissue Barriers 2018;6:1539595.

73. Prochazkova P, Roubalova R, Dvorak J, Tlaskalova-Hogenova H, Cermakova M, Tomasova P, Sediva B, Kuzma M, Bulant J, Bilej M, Hrabak P, Meisnerova E, Lambertova A, Papezova H. Microbiota, microbial metabolites, and barrier function in a patient with anorexia nervosa after fecal microbiota transplantation. Microorganisms 2019;7:338.

74. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235–243.

75. Hernández-Chiriláque C, Aranda CJ, Ocón B, Capitán-Cañadas F, Ortega-González M, Carrero JJ, Suárez MD, Zarruelo A, Sánchez de Medina F, Martínez-Augustin O. Germ-free and antibiotic-treated mice are highly susceptible to epithelial injury in DSS Colitis. J Crohns Colitis 2016;10:1324–1335.

76. Wu W, Sun M, Chen F, Cao AT, Liu H, Zhao Y, Huang X, Xiao Y, Yao S, Zhao Q, Liu Z, Cong Y. Microbiota metabolite short-chain fatty acid acetate promotes intestinal IgA response to microbiota which is mediated by GPR43. Mucosal Immunol 2017;10:946–956.

77. Macfarlane S, Macfarlane GT. Regulation of short-chain fatty acid production. Proc Nutr Soc 2003;62:67–72.

78. Nielsen DSG, Jensen BB, Theil PK, Nielsen TS, Knudsen KEB, Purup S. Effect of butyrate and...
fermentation products on epithelial integrity in a mucus-secreting human colon cell line. Journal of Functional Foods 2018;40:9–17.
80. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res 2007; 61:37–41.
81. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr 2009; 139:1619–1625.
82. Wang HB, Wang PY, Wang X, Wan YL, Liu YC. Butyrate enhances intestinal epithelial barrier function via up-regulation of tight junction protein claudin-1 transcription. Dig Dis Sci 2012;57:3126–3135.
83. Feng Y, Wang Y, Wang P, Huang Y, Wang F. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy. Cell Physiol Biochem 2018;49:190–205.
84. Roe AJ, McLaggan D, Davidson I, O’Byrne C, Booth IR. Perturbation of anion balance during inhibition of growth of Escherichia coli by weak acids. J Bacteriol 1998; 180:767–772.
85. Sivaprakasam S, Bhutia YD, Yang S, Ganapathy V. Short-chain fatty acid transporters: role in colonic homeostasis. Compr Physiol 2017;8:299–314.
86. Hald S. Effects of dietary fibres on gut microbiota, faecal short-chain fatty acids and intestinal inflammation [PhD thesis]. Aarhus, Denmark: Aarhus University Hospital, Aarhus, Denmark, 2015.
87. Diao H, Jiao AR, Yu B, Mao XB, Chen DW. Gastric infusion of short-chain fatty acids can improve intestinal barrier function in weaned piglets. Genes Nutr 2019; 14:4.
88. Hendriks T, Schnabl B. Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. J Intern Med 2019;286:32–40.
89. Zelante T, Iannitti RG, Cunha C, De Luca A, Giovannini G, Pieraccini G, Zecchi R, D’Angelo C, Massi-Benedetti C, Fallarino F, Carvalho A, Puccetti P, Romani L. Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal inflammation via interleukin-22. Immunity 2011;33:372–385.
90. Shimada Y, Kinoshita M, Harada K, Mizutani M, Masahata K, Kayama H, Takeda K. Commensal bacteria-dependent indole production enhances epithelial barrier function in the colon. PLoS One 2013;8:e80604.
91. Geng S, Cheng S, Li Y, Wen Z, Ma X, Jiang X, Wang Y, Han X. Faecal microbiota transplantation reduces susceptibility to epithelial injury and modulates tryptophan metabolism of the microbial community in a piglet model. J Crohns Colitis 2018;12:1359–1374.
92. Yu M, Wang Q, Ma Y, Li L, Yu K, Zhang Z, Chen G, Li X, Xiao W, Xu P, Yang H. Aryl hydrocarbon receptor activation modulates intestinal epithelial barrier function by maintaining tight junction integrity. Int J Biol Sci 2018; 14:69–77.
93. Teng Y, Ren Y, Sayed M, Hu X, Lei C, Kumar A, Hutchins E, Mu J, Deng Z, Luo C, Sundaram K, Sriwastva MK, Zhang L, Hsieh M, Reiman R, Haribabu B, Yan J, Jala VR, Miller DM, Van Keuren-Jensen K, Merchant ML, McClain CJ, Park JW, Egelmez NK, Zhang HG. Plant-derived exosomial MicroRNAs shape the gut microbiota. Cell Host Microbe 2018;24:637–652.e8.
94. Han B, Sheng B, Zhang Z, Pu A, Yin J, Wang Q, Yang K, Sun L, Yu M, Qiu Y, Xiao W, Yang H. Aryl hydrocarbon receptor activation in intestinal obstruction ameliorates intestinal barrier dysfunction via suppression of MLCK-MLC phosphorylation pathway. Shock 2016; 46:319–328.
95. Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R, Straube M, Jegou S, McQuilty C, Le Gall M, da Costa G, Lecornet E, Michaudel C, Modoux M, Gliot J, Bridonneau C, Sovran B, Dupraz L, Bado A, Richard ML, Langella P, Hansel B, Launay JM, Xavier RJ, Duboc H, Sokol H. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab 2018;28:737–749.e4.
96. Shao T, Zhao C, Li F, Gu Z, Liu L, Zhang L, Wang Y, He L, Liu Y, Liu Q, Chen Y, Donde H, Wang R, Jala VR, Barve S, Chen SY, Zhang X, Chen Y, McClain CJ, Feng W. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction. J Hepatol 2018; 69:886–895.
97. Kiss EA, Vonarbourg C, Kopfmann S, Hobelka E, Finke D, Esser C, Diefenbach A. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 2011;334:1561–1565.
98. Lee JS, Cella M, McDonald KG, Garlanda C, Gallagher AR, Grigorieva EF, Wilhelm C, Veldhoen M. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell 2011; 147:629–640.
99. Metidji A, Omenetti S, Crotta S, Li Y, Nye E, Ross E, Li V, Maradana MR, Schiering C, Stockinger B. The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity. Immunity 2019;50:1542.
100. Russo E, Giudici F, Fiorindi C, Ficari F, Scaringi S, Amedei A. Immunomodulating activity and therapeutic effects of short chain fatty acids and tryptophan postbiotics in inflammatory bowel disease. Front Immunol 2019;10:2754.
101. Dawson PA, Karpen SJ. Intestinal transport and metabolism of bile acids. J Lipid Res 2015;56:1085–1099.
102. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014;66:948–983.
acid action on tight junctions in a model colonic epithelium. Physiol Rep 2017;5:e13294.

105. Stanman LK, Holma R, Korpela R. High-fat-induced intestinal permeability dysfunction associated with altered fecal bile acids. World J Gastroenterol 2012;18:923–929.

106. Pavlidis P, Powell N, Vincent RP, Ehrlich D, Bjarnason I, Hayee B. Systematic review: bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence? Aliment Pharmacol Ther 2015;42:802–817.

107. Stanman LK, Holma R, Eggert A, Korpela R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. Am J Physiol Gastrointest Liver Physiol 2013;304:G227–G234.

108. Fort MM, Mozaffarian A, Stöver AG, Correia Jda S, Johnson DA, Crane RT, Ulevitch RJ, Persing DH, Bielefiedt-Ohmann H, Probst P, Jeffery E, Flingle SP, Hershberg RM. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol 2005;174:6416–6423.

109. Ticho AL, Malhotra P, Dudeja PK, Gill RK, Alrefai WA. Bile acid receptors and gastrointestinal functions. Liver Res 2019;33:31–39.

110. Raimondi F, Santoro P, Barone MV, Pappacoda S, Barretta ML, Nanayakkara M, Apicella C, Capasso L, Paludetto R. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008;294:G906–G913.

111. de Diego-Cabero N, Mereu A, Menoyo D, Holst JJ, Ipharraguerre IR. Bile acid mediated effects on gut integrity and performance of early weaned piglets. BMC Vet Res 2015;11:111.

112. Liu L, Liu Z, Li H, Cao Z, Li W, Song Z, Li X, Lu A, Lu C, Liu Y. Naturally occurring TPE-CA maintains gut microbiota and bile acids homeostasis via FXR signaling modulation of the gut-liver axis. Front Pharmacol 2020;11:12.

113. Maccioni L, Gao B, Leclercq S, Pirlot B, Horsmans Y, Barretta ML, Nanayakkara M, Apicella C, Capasso L, Paludetto R. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008;294:G906–G913.

114. Meroni M, Longo M, Dongiovanni P. Alcohol or gut microbiota: who is the guilty? Int J Mol Sci 2019;20:4568.

115. Cassard AM, Ciocan D. Microbiota, a key player in alcoholic liver disease. Clin Mol Hepatol 2018;24:100–107.

116. Hartmann P, Hovrath K, Horvath A, Chen P, Seebauer CT, Timary P, Leclercq I, Fouts D, Schnabl B, Stärkel P, Loomba R, Cote M, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. Modulation of the intestinal bile acid/farnesoid X receptor/ fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology 2018;67:2150–2166.

117. Cipriani S, Mercarelli A, Chini MG, Distrutti E, Renga B, Bifulco G, Baldelli F, Donini A, Fiorucci S. The bile acid receptor GPBAR1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS One 2011;6:e25637.

118. Schoeler M, Caesar R. Dietary lipids, gut microbiota and lipid metabolism. Rev Endocr Metab Disord 2019;20:461–472.

119. Roche HM, Terres AM, Black IB, Gibney MJ, Kelleher D. Fatty acids and epithelial permeability: effect of conjugated linoleic acid in Caco-2 cells. Gut 2001;48:797–802.

120. Chen Y, Yang B, Ross RP, Jin Y, Stanton C, Zhao J, Zhang H, Chen W. Orally administered CLA ameliorates DSS-induced colitis in mice via intestinal barrier improvement, oxidative stress reduction, and inflammatory cytokine and gut microbiota modulation. J Agric Food Chem 2019;67:13282–13298.

121. Ren Q, Yang B, Zhang H, Ross RP, Stanton C, Chen H, Chen W; c9, t11, c15-CLNA and 19, t11, c15-CLNA from Lactobacillus plantarum ZS2058 ameliorate dextran sodium sulfate-induced colitis in mice. J Agric Food Chem 2020;68:3758–3769.

122. Tofalo R, Cicchi S, Suzuki G. Polyamines and gut microbiota. Front Nutr 2019;6:16.

123. Timmons J, Chang ET, Wang JY, Rao RN. Polyamines and gut mucosal homeostasis. J Gastrointest Dig Syst 2012;2 Suppl 7:001.

124. Matsumoto M, Kurihara S, Kibe R, Ashida H, Benno Y. Longevity in mice is promoted by probiotic-induced suppression of colonic senescence dependent on upregulation of gut bacterial polyamine production. PLoS One 2011;6:e23652.

125. Michael AJ. Biosynthesis of polyamines and polyamine-containing molecules. Biochem J 2016;473:2315–2329.

126. Liu L, Guo X, Yao RN, Zou T, Xiao L, Yu T, Timmons JA, Turner DJ, Wang JY. Polyamines regulate E-cadherin transcription through c-Myc modulating intestinal epithelial barrier function. Am J Physiol Cell Physiol 2009;296:C801–C810.

127. Guo X, Rao RN, Liu L, Zou TT, Turner DJ, Bass BL, Wang JY. Regulation of adherens junctions and epithelial paracellular permeability: a novel function for polyamines. Am J Physiol Cell Physiol 2003;285:C1174–C1187.

128. Guo X, Rao RN, Liu L, Zou T, Keledjian KM, Boneva D, Marasa BS, Wang JY. Polyamines are necessary for synthesis and stability of occludin protein in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2005;288:G1159–G1169.

129. Heber D. Multitargeted therapy of cancer by ellagitannins. Cancer LEtt 2008;269:262–268.

130. Espin JC, Larrosa M, Garcia-Conesa MT, Tomas-Barberan F. Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med 2013;2013:270418.

131. Cerda B, Periago P, Espin JC, Tomas-Barberan FA. Identification of urolithin a as a metabolite produced by...
human colon microflora from ellagic acid and related compounds. J Agric Food Chem 2005;53:5571–5576.

132. Espin JC, Gonzalez-Barrio R, Cerda B, Lopez-Bote C, Rey Al, Tomas-Barberan FA. Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 2007;55:10476–10485.

133. Tomas-Barberan FA, Gonzalez-Sarrias A, Garcia-Villalba R, Nunez-Sanchez MA, Selma MV, Garcia-Conesa MT, Espin JC. Urolithins, the rescue of ‘old’ metabolites to understand a ‘new’ concept: metabolotypes as a nexus between phenolic metabolism, microbiota dysbiosis and host health status. Mol Nutr Food Res 2017;61. mmfr.201500901.

134. Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Cerda B, Espin JC, Parra S, Martinez-P, Tomas–Garcia-Villalba R, Beltran D, Espin JC, Selma MV, Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, Tomas-Barberan FA, Espin JC. Metabolism of ellagitannins in humans. J Agric Food Chem 2006;55:10476–10485.

135. Saha P, Yeoh BS, Singh R, Chandrasekar B, Vemula PK, Ryu D, Mouchiroud L, Andreux PA, Katsyuba E, Cerda B, Espin JC, Parra S, Martinez-P, Tomas–Garcia-Villalba R, Beltran D, Espin JC, Selma MV, Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, Tomas-Barberan FA, Espin JC. Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res 2014;58:1199–1211.

136. Larrosa M, Gonzalez-Sarrias A, Yanez-Gasco MJ, Selma MV, Azorin-Ortuno M, Moti S, Tomas-Barberan F, Dolaro P, Espin JC. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 2010;21:717–725.

137. Garcia-Villalba R, Beltran D, Espin JC, Selma MV, Tomas-Barberan FA. Time course production of urolithins from ellagic acid by human gut microbiota. J Agric Food Chem 2013;61:8797–8806.

138. Gonzalez-Sarrias A, Gimenez-Bastida JA, Garcia-Conesa MT, Gomez-Sanchez MB, Garcia-Talavera NV, Gil-Izquierdo A, Sanchez-Alvarez C, Fontana-Compano LO, Morga-Egea JP, Pastor-Quirante FA, Martinez-Diaz F, Tomas-Barberan FA, Espin JC. Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 2010;54:311–322.

139. Tomas-Barberan FA, Garcia-Villalba R, Gonzalez-Sarrias A, Selma MV, Espin JC. Ellagic acid metabolism by human gut microbiota: consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. J Agric Food Chem 2014;62:6535–6538.

140. Cerda B, Tomas-Barberan FA, Espin JC. Metabolism of antioxidant and chemopreventive ellagitannins from strawberries, raspberries, walnuts, and oak-aged wine in humans: identification of biomarkers and individual variability. J Agric Food Chem 2005;53:227–235.

141. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA, Li Z, Chen S, Thames G, Zerlin A, Nguyen M, Wang D, Dreher M, Heber D. Pomegranate juice and extracts provide similar levels of plasma and urinary ellagittannin metabolites in human subjects. J Med Food 2008;11:390–394.

142. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagittannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481–2485.

143. Nunez-Sanchez MA, Garcia-Villalba R, Monedero-Saiz T, Garcia-Talavera NV, Gomez-Sanchez MB, Sanchez-Alvarez C, Garcia-Albert AM, Rodriguez-Gil FJ, Ruiz-Marin M, Pastor-Quirante FA, Martinez-Diaz F, Yanez-Gascon MJ, Gonzalez-Sarrias A, Tomas-Barberan FA, Espin JC. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med 2016;22:879–888.

144. Saha P, Yeoh BS, Singh R, Chandrasekar B, Vemula PK, Haribabu B, Vijay-Kumar M, Jala VR. Gut microbiota conversion of dietary ellagic acid into bioactive phytoceutical urolithin A inhibits heme peroxidases. PLoS One 2016;11:e0156811.

145. Gaya P, Peiroténa A, Medina M, Álvarezb I, Landete JM, Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid. J Nutr Biochem 2017;108:289–297.

146. Selma MV, Beltran D, Garcia-Villalba R, Espin JC, Tomas-Barberan FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct 2014;5:1779–1784.

147. Guglielmetti S, Bernardi S, Del Bo C, Cherubini A, Porini M, Gargari G, Hidalgo-Liberona N, Gonzalez-Dominguez R, Peron G, Zamora-Ros R, Winterbone MS, Kirkup B, Kroon PA, Andres-Lacueva C, Riso P. Effect of a polyphenol-rich dietary pattern on intestinal permeability and gut and blood(-)brain barrier permeability and protect murine microglia against LPS-induced inflammation. Metabolics 2019;7:9–72.

148. Guglielmetti S, Bernardi S, Del Bo C, Cherubini A, Porini M, Gargari G, Hidalgo-Liberona N, Gonzalez-Dominguez R, Peron G, Zamora-Ros R, Winterbone MS, Kirkup B, Kroon PA, Andres-Lacueva C, Riso P. Effect of a polyphenol-rich dietary pattern on intestinal permeability and gut and blood(-)brain barrier permeability and protect murine microglia against LPS-induced inflammation. J Nutr Biochem 2014;21:717–725.

149. Heilman J, Andreux P, Tran N, Rinsch C, Blancone-Bose W. Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid. Food Chem Toxicol 2017;108:289–297.

150. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D. Pomegranate juice ellagittannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481–2485.

151. Johnson SL, Kirk RD, DaSilva NA, Ma H, Seeram NP, Bertin MJ. Polyphenol microbial metabolites exhibit gut and brain protective properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 2010;21:717–725.

152. Gaya P, Peiroténa A, Medina M, Álvarezb I, Landete JM, Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid. J Nutr Biochem 2018;45:99–99.

153. Gaya P, Peiroténa A, Medina M, Álvarezb I, Landete JM, Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid. J Nutr Biochem 2018;45:99–99.

154. Gaya P, Peiroténa A, Medina M, Álvarezb I, Landete JM, Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid. J Nutr Biochem 2018;45:99–99.

155. Gaya P, Peiroténa A, Medina M, Álvarezb I, Landete JM, Bifidobacterium pseudocatenulatum INIA P815: The first bacterium able to produce urolithins A and B from ellagic acid. J Nutr Biochem 2018;45:99–99.
153. Ong HS, Yim HCH. Microbial factors in inflammatory diseases and cancers. Adv Exp Med Biol 2017; 1024:153–174.
154. Mu C, Yang Y, Zhu W. Crosstalk between the immune receptors and gut microbiota. Curr Protein Pept Sci 2015;16:622–631.
155. Marques R, Boneca IG. Expression and functional importance of innate immune receptors by intestinal epithelial cells. Cell Mol Life Sci 2011;68:3661–3673.
156. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 2011;108 Suppl 1:4607–4614.
157. Creagh EM, O’Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol 2006;27:352–357.
158. Ey B, Eyking A, Gerken G, Podolsky DK, Cario E. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 2009;284:22332–22343.
159. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007;132:1359–1374.
160. Wang W, Xia T, Yu X. Wogonin suppresses inflammatory response and maintains intestinal barrier function via TLR4-MyD88-TAK1-mediated NF-kappaB pathway in vitro. Inflamm Res 2015;64:423–431.
161. Luo H, Guo P, Zhou Q. Role of TLR4/NF-kappaB in damage to intestinal mucosa barrier function and bacterial translocation in rats exposed to hypoxia. PLoS One 2012;7:e46291.
162. Ungaro R, Fukata M, Hsu D, Hernandez M, Chen A, Xu R, Sotolongo J, Espana C, Zaia JA, Elson L, Mayer L, Kosco-Vilbois M, Abreu MT. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009;296:G1167–G1179.
163. Peterson CY, Costantini TW, Loomis WH, Putnam JG, Wolf P, Bansal V, Elieceiri BP, Baird A, Coimbra R. Toll-like receptor 5 contributes to enteric infection. Infect Immun 2007;75:545–552.
164. Chassaing B, Ley RE, Gewirtz AT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology 2014;147:1363–1377.e17.
165. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, Sitaraman SV, Neish AS, Uematsu S, Akira S, Williams IR, Gewirtz AT. Deletion of TLR5 results in spontaneous colitis in mice. J Clin Invest 2007;117:3909–3921.
166. Leifer CA, McConkey C, Li S, Chassaing B, Gewirtz AT, Ley RE. Linking genetic variation in human Toll-like receptor 5 genes to the gut microbiome’s potential to cause inflammation. Immunol Lett 2014;162:3–9.
167. Vijay-Kumar M, Aitken JD, Gewirtz AT. Toll like receptor-5: protecting the gut from enteric microbes. Semin Immunopathol 2008;30:11–21.
168. Lopetuso LR, Jia R, Wang XM, Jia LG, Petito V, Goodman WA, Meddings JB, Cominelli F, Reuter BK, Pizarro TT. Epithelial-specific Toll-like receptor (TLR5) activation mediates barrier dysfunction in experimental ileitis. Inflamm Bowel Dis 2017;23:392–403.
169. Carvalho FA, Aitken JD, Gewirtz AT, Vijay-Kumar M. TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage. Mucosal Immunol 2011;4:102–111.
170. Rose WA 2nd, Sakamoto K, Leifer CA. TLR9 is important for protection against intestinal damage and for intestinal repair. Sci Rep 2012;2:574.
171. Parlato M, Yeretzssian G. NOD-like receptors in intestinal homeostasis and epithelial tissue repair. Int J Mol Sci 2014;15:9594–9627.
172. Chassaing B, Ley RE. Effectors of NLRs in the intestine: innate sensing, cell death, and disease. Immunol Rev 2012;254:25–36.
173. Chen KY, Shaw MH, Redondo G, Núñez G. The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 2008;68:10060–10067.
174. Watanabe T, Asano N, Murray PJ, Ozato K, Tailor P, Fuss IJ, Kitani A, Strober W. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest 2008;118:545–559.
175. Macho Fernandez E, Valenti V, Rockel C, Hermann C, Pot B, Boneca IG, Grangette C. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD2-mediated recognition of a specific peptidoglycan-derived muropeptide. Gut 2011;60:1050–1059.
176. Natividad JM, Petit V, Huang X, de Palma G, Jury J, Sanz Y, Philpott D, Garcia Rodenas CL, McCoy KD, Verdu EF. Commensal and probiotic bacteria influence intestinal barrier function and susceptibility to colitis in Nod1−/−; Nod2−/− mice. Inflamm Bowel Dis 2012;18:1434–1446.
177. Couturier-Maillard A, Secher T, Rehman A, Normand S, Degregorius J, Lisovski J, Bresson C, Furst E, Kummer W, Rosenstiel P, Minghetti L, Chamaillard M. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 2013;123:700–711.
178. Arpaia N, Campbell C, Fan X, D’Ikly S, van der Veeken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffer PJ, Rudensky AY. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013;504:451–455.
179. Konieczna P, Foratl R, Ziegler M, Frei R, Lehrbass D, Lauener RP, Aitken JD, Gewirtz AT. Toll like receptor-5: protecting the gut from enteric microbes. Semin Immunopathol 2008;30:11–21.
201. Mazmanian SK, Liu CH, Tzianobos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directly matures the host immune system. Cell 2005; 122:107–118.

182. Kayama H, Takeda K. Manipulation of epithelial integrity and mucosal immunity by host and microbiota-derived metabolites. Eur J Immunol 2020;50:921–931.

183. Allaire JM, Crowley SM, Law HT, Chang SY, Ko HJ, Vallance BA. The intestinal epithelium: central coordinator of mucosal immunity. Trends Immunol 2018;39:677–696.

184. Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, Takahashi M, Fukuda NN, Murakami S, Miyauchi E, Hino S, Atarashi K, Onawa S, Fujimura Y, Lockett T, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446–450.

185. Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 2015;64:1794–1803.

186. Duan F, Curtis KL, March JC. Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 2008;74:7437–7438.

187. Khare V, Krmic A, Frick A, Gmainer C, Asboth M, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446–450.

188. Khare V, Krmic A, Frick A, Gmainer C, Asboth M, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H, Clarke JM, Topping DL, Tomita M, Hori S, Ohara O, Morita T, Koseki H, Kikuchi J, Honda K, Hase K, Ohno H. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013;504:446–450.

189. Powrie F, Leach MW, Mauze S, Menon S, Caddle LB, Coffman RL. Inhibition of Th1 responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cells. Immunity 1994;1:553–562.

190. Noth R, Stuber E, Hasler M, Arlt A, Li H-S, Biswas A, Ong MLDM, Jiang Z-H, Choi W, Li Y, Zeng H, Chen J, Lin Z, Xian Y, Huang X, Xie J, Su Z. Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway. Pharmacol Res 2020;152:104603.

191. Atarashi K, Tanoue T, Oshima K, Suda W, Nagano Y, Jimenez K, Lang M, Baumgartner M, Esvatliev R, Gasche C. Mesalamine and azathioprine modulate junctional complexes and restore epithelial barrier function in intestinal inflammation. Sci Rep 2019;9:2842.

192. Duan F, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 2015;64:1794–1803.

193. Duan F, Curtis KL, March JC. Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. Appl Environ Microbiol 2008;74:7437–7438.

194. Schmidt EKA, Torres-Espin A, Raposo PJF, Madsen KL, Kigerl KA, Popovich PG, Fenrich KK, Fouad K. Fecal transplant prevents gut dysbiosis and anxiety-like behaviour after spinal cord injury in rats. PLoS One 2020;15:e0262128.

195. Li C, Ai G, Wang Y, Lu Q, Luo C, Tan L, Lin G, Liu Y, Li Y, Zeng H, Chen J, Lin Z, Xian Y, Huang X, Xie J, Su Z. Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway. Pharmacol Res 2020;152:104603.

196. Duan F, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 2015;64:1794–1803.

197. Li C, Ai G, Wang Y, Lu Q, Luo C, Tan L, Lin G, Liu Y, Li Y, Zeng H, Chen J, Lin Z, Xian Y, Huang X, Xie J, Su Z. Oxyberberine, a novel gut microbiota-mediated metabolite of berberine, possesses superior anti-colitis effect: Impact on intestinal epithelial barrier, gut microbiota profile and TLR4-MyD88-NF-kappaB pathway. Pharmacol Res 2020;152:104603.

198. Duan F, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 2015;64:1794–1803.

199. Wang Y, Yang J, Wang W, Sanidad KZ, Cinelli MA, Wan D, Hwang SH, Kim D, Lee KSS, Xiao H, Hammock BD, Zhang Q. Soluble epoxide hydrolase is an endogenous regulator of obesity-induced intestinal barrier dysfunction and bacterial translocation. Proc Natl Acad Sci U S A 2020;117:8431–8436.

200. van der Giessen J, van der Woude CJ, Peppelenbosch MP, Fuhler GM. A direct effect of sex hormones on epithelial barrier function in inflammatory bowel disease models. Cells 2019;8:261.

201. Zhao M, Fitting S, Kamen DL, Oates JC, Gilkeson G, Jiang W. Progesterone decreases gut permeability through upregulating occludin expression in primary human gut tissues and Caco-2 cells. Sci Rep 2019;9:8367.

202. Bi J, Zhang J, Ren Y, Du Z, Li T, Wang T, Zhang L, Wang M, Wu Z, Lv Y, Wu R. Irisin reverses intestinal epithelial barrier dysfunction during intestinal injury via binding to the integrin alphaVbeta5 receptor. J Cell Mol Med 2020;24:996–1009.

203. Yang J, Guo Y, Henning S, Chan B, Long J, Zhong J, Acin-Perez P, Petcherski A, Shirihaï O, Heber D, Li Z. Ellagic acid and its microbial metabolite urolithin a alleviate diet-induced insulin resistance in mice (OR24-03-19). Curr Dev Nutr 2019;3, rzz031.OR24-03-19.

204. Wang T, Yao W, Li J, Shao Y, He Q, Xia J, Huang F. Dietary garcinol supplementation improves diarrhea and intestinal barrier function associated with its modulation of gut microbiota in weaned piglets. J Anim Sci Biotechnol 2020;11:12.
205. Di Caro V, Alcamo AM, Cummings JL, Clark RSB, Novak EA, Mollen KP, Morowitz MJ, Aneja RK. Effect of dietary cellulose supplementation on gut barrier function and apoptosis in a murine model of endotoxemia. PLoS One 2019;14:e0224838.

206. Piton G, Capellier G. Biomarkers of gut barrier failure in the ICU. Curr Opin Crit Care 2016;22:152–160.

207. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019;68:1516–1526.

Received July 23, 2020. Accepted February 12, 2021.

Correspondence
Address requests for correspondence to: Venkatakrishna Rao Jala, PhD, Department of Microbiology and Immunology, James Graham Brown Cancer Center, 505 South Hancock Street #323, Louisville, KY 40202. e-mail: jvrao001@louisville.edu; fax: (502) 852-2123.

Acknowledgments
The authors would like to thank Drs Juhi A. Bagaitkar and Fred Ausbel for proof reading and insightful discussions.

Conflicts of interest
This author disclose the following: Venkatakrishna Rao Jala is one of the scientific co-founders of Artus Therapeutics. The remaining authors disclose no conflicts.

Funding
Venkatakrishna Rao Jala is supported by National Institutes of Health (NIH)/National Cancer Institute (R21CA216090), NIH/National Cancer Institute (CA191683), NIH/National Institute of General Medical Sciences CoBRE grant (P20GM125504-01), P30ES030283 (NIH/National Institute of Environmental Health Sciences), and the Jewish Heritage Fund for Excellence Research Enhancement Grant and James Graham Brown Cancer Center.